Auflistung nach Autor "Galasko, Douglas"

Sortiert nach: Sortierung: Ergebnisse:

  • Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation 
    Dubois, Bruno; Villain, Nicolas; Schneider, Lon; Fox, Nick C.; Campbell, Noll; Galasko, Douglas; Kivipelto, Miia; Jessen, Frank; Hanseeuw, Bernard J.; Boada, Mercè; Barkhof, Frederik; Nordberg, Agneta; Froelich, Lutz; Waldemar, Gunhild; Frederiksen, Kristian Steen; Padovani, Alessandro; Planche, Vincent; Rowe, Christopher C.; Bejanin, Alexandre; Allegri, Ricardo Francisco (American Medical Association, 2024-11-01)
    Importance: Since 2018, a movement has emerged to define Alzheimer disease (AD) as a purely biological entity based on biomarker findings. The recent revision of the Alzheimer Association (AA) criteria for AD furthers this ...
  • Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial 
    Wagemann, Olivia; Liu, Haiyan; Wang, Guoqiao; Shi, Xinyu; Bittner, Tobias; Scelsi, Marzia A.; Farlow, Martin R.; Clifford, David B.; Supnet Bell, Charlene; Santacruz, Anna M.; Aschenbrenner, Andrew J.; Hassenstab, Jason; Benzinger, Tammie L.S.; Gordon, Brian A.; Coalier, Kelley A.; Cruchaga, Carlos; Ibanez, Laura; Perrin, Richard J.; Xiong, Chengjie; Li, Yan; Morris, John C.; Lah, James J.; Berman, Sarah B.; Roberson, Erik D.; van Dyck, Christopher H.; Galasko, Douglas; Gauthier, Serge; Hsiung, Ging-Yuek R.; Brooks, William S.; Pariente, Jérémie; Mummery, Catherine J.; Day, Gregory S.; Ringman, John M.; Chrem Méndez, Patricio Alexis; Dominantly Inherited Alzheimer Network–Trials Unit (American Medical Association, 2024-06-01)
    Importance: Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited ...

DSpace Suche

Stöbern

Mein Benutzerkonto